Concordia Healthcare (CHEHF) 31.6503 $CHEHF
Eisai Sells U.S. Rights to Zonegran® (zonisamide) Capsules to Concordia Pharmaceuticals Inc.
PR Newswire - Wed Sep 03, 6:00AM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into an agreement with Concordia Pharmaceuticals Inc. ("Concordia"
, a subsidiary of Concordia Healthcare Corp., to purchase Eisai's U.S. and Puerto Rican commercialization and distribution rights to Zonegran. As part of the deal terms, Eisai will receive full payment from Concordia upon closing. In addition, Eisai and Concordia are expected to enter into a supply agreement under which Eisai will serve as Concordia's supplier of Zonegran for the U.S. and Puerto Rican markets.
Concordia Healthcare Announces Agreement to Acquire Zonegran® in the United States and Puerto Rico
CNW Group - Wed Sep 03, 6:00AM CDT
Concordia Healthcare Corp. (Concordia or the Company) (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Concordia Pharmaceuticals Inc., has entered into a definitive agreement with Eisai Inc. ("Eisai" to acquire Zonegran® for commercialization and sale in the United States, including Puerto Rico.
Concordia Healthcare Corp. enters into collaboration agreement with Orphan Canada
PR Newswire - Tue Sep 02, 6:00AM CDT
Concordia Healthcare Corp. ("Concordia" (TSX:CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc. ("Pinnacle" , a biopharmaceutical research and development company specializing in rare diseases, has signed a collaboration agreement for PHOTOFRIN® (porfimer sodium) with Orphan Canada, a Toronto-based specialty pharmaceutical company that in‐licenses therapies for rare disorders and specialty medicines within Canada. Under the agreement, Pinnacle and Orphan Canada will partner to support the continued supply of Photodynamic Therapy (PDT) using PHOTOFRIN in Canada.
Concordia Healthcare Corp. Announces Financial and Operational Results for its Second Quarter, Ended June 30, 2014
CNW Group - Wed Aug 13, 4:00PM CDT
Concordia Healthcare Corp. ("Concordia" or the "Company" (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and six months ended June 30, 2014.
Concordia Healthcare Corp. announces first patients enrolled in Phase 2 clinical trial using Photodynamic Therapy with PHOTOFRIN(R) for patients with mesothelioma
CNW Group - Mon Aug 11, 6:00AM CDT
Concordia Healthcare Corp. ("Concordia" (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, enrolled the first patients in a randomized Phase 2 trial to evaluate Photodynamic Therapy (PDT) with PHOTOFRIN® for patients with epithelioid malignant pleural mesothelioma (MPM).
Concordia Healthcare Corp. initiates Phase 3 bile duct cancer trial using photodynamic therapy with PHOTOFRIN®
PR Newswire - Tue Aug 05, 6:00AM CDT
Thomas Jefferson University Hospital is first site opened, more sites scheduled in August
Concordia Healthcare Corp. to host second quarter 2014 results conference call
CNW Group - Thu Jul 31, 9:30AM CDT
Concordia Healthcare Corp. ("Concordia" (TSX: CXR) (OTCQX: CHEHF) today announced it will release its second quarter 2014 financial results after market close on Wednesday, August 13, 2014. The Company will subsequently hold a conference call on Thursday, August 14, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update.
Concordia Healthcare Corp. Reports Results of Annual General and Special Meeting of Shareholders
CNW Group - Fri Jun 27, 2:46PM CDT
Concordia Healthcare Corp. ("Concordia" (TSX: CXR) (OTCQX: CHEHF), today announced that all of the nominees listed in the Management Information Circular of Concordia, dated May 23, 2014, for the 2014 Annual and Special Meeting of Shareholders held on June 27, 2014, in Toronto, Ontario, (the "Meeting" were elected as Directors of Concordia. The six (6) candidates nominated for election were elected by a majority of the shareholders present in person or represented by proxy at the Meeting, as follows:
Concordia Healthcare to Present at Bloom Burton & Co. Healthcare Investor Conference
CNW Group - Thu Jun 12, 1:00PM CDT
Concordia Healthcare Corp. (TSX: CXR) (OTCQX: CHEHF), today announced that Mark Thompson, Chief Executive Officer, will present at the 2014 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario. Concordia's presentation will take place on Wednesday, June 18, 2014, at 11:00 a.m. ET.
Concordia Healthcare Announces Fiscal 2013 Results (May 2013 - December 2013)
PR Newswire - Mon Mar 31, 6:00AM CDT
Company's board approves an annualized US$0.30 dividend -
FDA Approves Optiguide® DCYL700 Fiber Optic Diffuser Series flexible fiber
PR Newswire - Wed Mar 26, 7:00AM CDT
Concordia Healthcare Corp. ("Concordia" TSX:CXR) announced today that its subsidiary Pinnacle Biologics, Inc. ("Pinnacle" , a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration (FDA) premarket supplemental approval (PMA) for its Optiguide® DCYL700 Fiber Optic Diffuser Series flexible fiber.
Concordia Healthcare Corp. to Host Fiscal 2013 Year-End Results Conference Call
CNW Group - Mon Mar 24, 3:00PM CDT
Concordia Healthcare Corp. ("Concordia" (TSX: CXR) (OTCQX: CHEHF) today announced it will release its 2013 year-end financial results on Monday, March 31, 2014, before market open. The Company will subsequently hold a conference call on Monday, March 31, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update.
Concordia Healthcare Announces Agreement to Acquire Donnatal®
PR Newswire - Thu Mar 20, 6:30AM CDT
Concordia Healthcare Corp. (Concordia or the Company) (TSX: CXR) (OTCQX: CHEHF), announced today that it has entered into a definitive agreement to acquire Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS" and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals" .
Eisai Sells U.S. Rights to Zonegran® (zonisamide) Capsules to Concordia Pharmaceuticals Inc.
PR Newswire - Wed Sep 03, 6:00AM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into an agreement with Concordia Pharmaceuticals Inc. ("Concordia"
, a subsidiary of Concordia Healthcare Corp., to purchase Eisai's U.S. and Puerto Rican commercialization and distribution rights to Zonegran. As part of the deal terms, Eisai will receive full payment from Concordia upon closing. In addition, Eisai and Concordia are expected to enter into a supply agreement under which Eisai will serve as Concordia's supplier of Zonegran for the U.S. and Puerto Rican markets. Concordia Healthcare Announces Agreement to Acquire Zonegran® in the United States and Puerto Rico
CNW Group - Wed Sep 03, 6:00AM CDT
Concordia Healthcare Corp. (Concordia or the Company) (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Concordia Pharmaceuticals Inc., has entered into a definitive agreement with Eisai Inc. ("Eisai"
to acquire Zonegran® for commercialization and sale in the United States, including Puerto Rico. Concordia Healthcare Corp. enters into collaboration agreement with Orphan Canada
PR Newswire - Tue Sep 02, 6:00AM CDT
Concordia Healthcare Corp. ("Concordia"
(TSX:CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc. ("Pinnacle" , a biopharmaceutical research and development company specializing in rare diseases, has signed a collaboration agreement for PHOTOFRIN® (porfimer sodium) with Orphan Canada, a Toronto-based specialty pharmaceutical company that in‐licenses therapies for rare disorders and specialty medicines within Canada. Under the agreement, Pinnacle and Orphan Canada will partner to support the continued supply of Photodynamic Therapy (PDT) using PHOTOFRIN in Canada. Concordia Healthcare Corp. Announces Financial and Operational Results for its Second Quarter, Ended June 30, 2014
CNW Group - Wed Aug 13, 4:00PM CDT
Concordia Healthcare Corp. ("Concordia" or the "Company"
(TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and six months ended June 30, 2014. Concordia Healthcare Corp. announces first patients enrolled in Phase 2 clinical trial using Photodynamic Therapy with PHOTOFRIN(R) for patients with mesothelioma
CNW Group - Mon Aug 11, 6:00AM CDT
Concordia Healthcare Corp. ("Concordia"
(TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, enrolled the first patients in a randomized Phase 2 trial to evaluate Photodynamic Therapy (PDT) with PHOTOFRIN® for patients with epithelioid malignant pleural mesothelioma (MPM). Concordia Healthcare Corp. initiates Phase 3 bile duct cancer trial using photodynamic therapy with PHOTOFRIN®
PR Newswire - Tue Aug 05, 6:00AM CDT
Thomas Jefferson University Hospital is first site opened, more sites scheduled in August
Concordia Healthcare Corp. to host second quarter 2014 results conference call
CNW Group - Thu Jul 31, 9:30AM CDT
Concordia Healthcare Corp. ("Concordia"
(TSX: CXR) (OTCQX: CHEHF) today announced it will release its second quarter 2014 financial results after market close on Wednesday, August 13, 2014. The Company will subsequently hold a conference call on Thursday, August 14, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update. Concordia Healthcare Corp. Reports Results of Annual General and Special Meeting of Shareholders
CNW Group - Fri Jun 27, 2:46PM CDT
Concordia Healthcare Corp. ("Concordia"
(TSX: CXR) (OTCQX: CHEHF), today announced that all of the nominees listed in the Management Information Circular of Concordia, dated May 23, 2014, for the 2014 Annual and Special Meeting of Shareholders held on June 27, 2014, in Toronto, Ontario, (the "Meeting" were elected as Directors of Concordia. The six (6) candidates nominated for election were elected by a majority of the shareholders present in person or represented by proxy at the Meeting, as follows: Concordia Healthcare to Present at Bloom Burton & Co. Healthcare Investor Conference
CNW Group - Thu Jun 12, 1:00PM CDT
Concordia Healthcare Corp. (TSX: CXR) (OTCQX: CHEHF), today announced that Mark Thompson, Chief Executive Officer, will present at the 2014 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario. Concordia's presentation will take place on Wednesday, June 18, 2014, at 11:00 a.m. ET.
Concordia Healthcare Announces Fiscal 2013 Results (May 2013 - December 2013)
PR Newswire - Mon Mar 31, 6:00AM CDT
Company's board approves an annualized US$0.30 dividend -
FDA Approves Optiguide® DCYL700 Fiber Optic Diffuser Series flexible fiber
PR Newswire - Wed Mar 26, 7:00AM CDT
Concordia Healthcare Corp. ("Concordia" TSX:CXR) announced today that its subsidiary Pinnacle Biologics, Inc. ("Pinnacle"
, a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration (FDA) premarket supplemental approval (PMA) for its Optiguide® DCYL700 Fiber Optic Diffuser Series flexible fiber. Concordia Healthcare Corp. to Host Fiscal 2013 Year-End Results Conference Call
CNW Group - Mon Mar 24, 3:00PM CDT
Concordia Healthcare Corp. ("Concordia"
(TSX: CXR) (OTCQX: CHEHF) today announced it will release its 2013 year-end financial results on Monday, March 31, 2014, before market open. The Company will subsequently hold a conference call on Monday, March 31, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update. Concordia Healthcare Announces Agreement to Acquire Donnatal®
PR Newswire - Thu Mar 20, 6:30AM CDT
Concordia Healthcare Corp. (Concordia or the Company) (TSX: CXR) (OTCQX: CHEHF), announced today that it has entered into a definitive agreement to acquire Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS"
and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals" . 
